PDA and the FDA: Regulatory Status
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
Pentadeca Arginate is not an FDA-approved drug, and neither is BPC-157. Based on FDA materials reviewed on July 22, 2026, BPC-157 has a complicated compounding history and remains outside the approved-drug and lawful-dietary-supplement pathways.
Based on FDA materials reviewed July 22, 2026. Not legal advice; the federal record may change. (No direct study of Pentadeca Arginate was found for this statement.)
Not FDA-approved
No direct evidence identifiedThere is no FDA-approved drug product called Pentadeca Arginate or BPC-157. U.S. guidance describes BPC-157 as an unapproved drug that is also not a lawful dietary ingredient.[3],[1]
The compounding history (503A)
BPC-157 was evaluated in the FDA’s bulk-drug-substances process for compounding under section 503A. The FDA placed it in a category associated with significant safety concerns — citing potential immunogenicity, impurity and characterization challenges, and limited human safety data — rather than the category eligible for the interim compounding policy.[1],[2]
Proposed vs. final action
Based on FDA materials reviewed on July 22, 2026, the nominations for BPC-157 (and TB-500) were withdrawn and the substances were removed from that safety-risk category, but they were not moved to the list of substances permitted for compounding, and neither has an approved-drug status or a recognized USP/NF monograph. This describes the current federal regulatory record and is not legal advice.
Common misreadings to avoid
- A substance appearing in an FDA database is not the same as being FDA-approved.
- Availability from a compounding pharmacy does not mean FDA approval.
- A nomination or committee discussion is not a final FDA decision.
- "Research use only" does not mean approved for human use.
This can change
The FDA position may change as additional reviews or rulemaking occur. Always check current FDA sources for the latest status.[1]
Frequently asked questions
Is PDA legal?
Legal status is nuanced and can vary; this page describes the federal regulatory record and is not legal advice. Neither PDA nor BPC-157 is an FDA-approved drug.
Does a UNII or database listing mean approval?
No. A database listing or identifier does not mean a substance is FDA-approved.
References
3 peer-reviewed journal sources and 3 additional authoritative references. Every reference supports a specific statement above.
- [1] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory
- [2] U.S. Food and Drug Administration (2025). Certain bulk drug substances for use in compounding that may present significant safety risks. FDA.gov, Regulatory information (compounding safety). View source Government / regulatory
- [3] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory
- [4] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [5] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [6] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal